3
3
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T1637 | Deferoxamine Mesylate | desferrioxamine B,Desferrioxamine B mesylate,DFO,DFOM | Mitophagy , Beta Amyloid , Others , Ferroptosis , HIF/HIF Prolyl-Hydroxylase , Autophagy |
Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and i... | |||
T124358 | Deferoxamine | Deferoxamine B,Desferrioxamine B | Apoptosis , Antioxidant , HIF , Autophagy |
Deferoxamine(Desferrioxamine B) is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may imp... | |||
T18971 | 1,8-Diazafluoren-9-one | DFO,9H-1,8-Diazafluoren-9-one | Others |
1,8-Diazafluoren-9-one (DFO) is used to find fingerprints on porous surfaces. |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPK-01413 | H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) | Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of... | |||
TMPK-01416 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we... | |||
TMPK-01412 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we... |